Recall Z-1025-2022
Siemens Healthcare Diagnostics, Inc. · initiated March 3, 2022
Class II – products that might cause a temporary health problem or pose a slight threat of a serious nature
Product
ADVIA Centaur Enhanced Estradiol (eE2) (REF) 500T - In vitro diagnostic use in the quantitative detection of estradiol SMN: 10697757 All lots
Codes / lots: All lot numbers UDI: (01)00630414591056(10)13852076(17)20220115 (01)00630414591056(10)46894074(17)20211028 (01)00630414591056(10)89042083(17)20220805
Reason for recall
Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient results
FDA-determined cause: Under Investigation by firm
Action taken
Siemens issued an Urgent Medical Device Correction AIMC 22-03.A.US and Urgent Field Safety Notice AIMC 22-03.A.OUS on 3/3/22. Letter states reason, health risk and action to take: Customers must discontinue use of plasma specimens for testing with the Atellica IM and ADVIA Centaur eE2 assays until further notice. Customers may continue to use the Atellica IM eE2 and ADVIA Centaur eE2 assays with serum specimens. Please review this letter with your Medical Director. Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days. If you have received any complaints of illness or adverse events associated with the products listed in Table 1, immediately contact your local Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative. Please retain this letter with your laboratory records and forward this letter to those who may have received this product. Questions: contact your Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative
Details
- Recall number
- Z-1025-2022
- Initiated
- March 3, 2022
- Product code
- CHP – Radioimmunoassay, Estradiol
- Quantity
- 88 units
- Distribution
- Worldwide distribution - US Nationwide and the countries of Austria, Belgium, Brazil, Bulgaria, Burkina, Faso Country AG, Cyprus, Denmark, Egypt, Estonia, Finland, France, French Polynesia, Georgia, Greece, Guadeloupe, India, Ireland, Israel, Italy, Kazakhstan, Latvia, Lithuania, Macedonia, Malta, Morocco, Nepal, Netherlands, Norway, Palestinian Ter, Paraguay, Poland, Portugal, Qatar, Romania…
- Recalling firm
- Siemens Healthcare Diagnostics, Inc., East Walpole, MA
Other products in the same recall event
| Recall | Product | Initiated |
|---|---|---|
| Z-1020-2022 Class II | Atellica IM Enhanced Estradiol (eE2) 100T - In vitro diagnostic use in the quantitative…Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient… | 03/03/2022Open, Classified |
| Z-1021-2022 Class II | Atellica IM Enhanced Estradiol (eE2) 500T - In vitro diagnostic use in the quantitative…Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient… | 03/03/2022Open, Classified |
| Z-1022-2022 Class II | Atellica IM Enhanced Estradiol (eE2) (REF) 500T - In vitro diagnostic use in the…Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient… | 03/03/2022Open, Classified |
| Z-1023-2022 Class II | ADVIA Centaur Enhanced Estradiol (eE2) 100T - In vitro diagnostic use in the…Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient… | 03/03/2022Open, Classified |
| Z-1024-2022 Class II | ADVIA Centaur Enhanced Estradiol (eE2) 500T - In vitro diagnostic use in the…Falsely Elevated Results Observed with Plasma Specimens, could lead a clinician to misinterpret patient… | 03/03/2022Open, Classified |